证券代码：688189 证券简称：南新制药 公告编号：2026-013 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 截至 2026 年 3 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 2,288,014 股，占公司总股本 274,400,000 股的比例为 0.83%，回购成交的最高价为 8.92 元/股，最低价为 7.02 元/股，支付的资金总额 为人民币 19,245,862.56 元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 2026 年 3 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 169,800 股，占公司总股本 274,400,000 股的比例为 0.06%，回购成交的最 高价为 7.84 元/股，最低价为 7.77 元/股，支付的资金总额为人民币 1,327,248.02 元（不含印花税、交易佣金等交易费用）。 | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 ...

证券代码：688189 证券简称：南新制药 公告编号：2026-012 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。公司现将回购股份进展情况公告如下： 2026 年 2 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 208,000 股，占公司总股本 274,400,000 股的比例为 0.08%，回购成交的最 高价为 8.59 元/股，最低价为 8.52 元/股，支付的资金总额为人民币 1,780,585.46 元（不含印花税、交易佣金等交易费用）。 截至 2026 年 2 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 2,118,214 股，占公司总股本 274,400,000 股的比 ...

Core Viewpoint - The company reported a significant decline in revenue and increased losses for the year 2025, attributed to intensified market competition and reduced demand due to fewer flu cases in the domestic market [2][3]. Financial Performance - The company achieved a revenue of 142 million yuan in 2025, a year-on-year decrease of 46.09% [2]. - The net profit attributable to shareholders was a loss of 137 million yuan, compared to a loss of 357 million yuan in the previous year [2]. - The non-recurring net profit also showed a loss of 139 million yuan, slightly better than the loss of 359 million yuan in the previous year [2]. - The basic earnings per share were -0.5006 yuan, with a weighted average return on equity of -15.84%, an increase of 16.03 percentage points from the previous year [2][10]. Market Conditions - The decline in revenue and gross margin was influenced by the ongoing implementation of centralized procurement policies in the domestic pharmaceutical industry and the introduction of competing products [3]. - The company maintained a high level of R&D investment to sustain its core competitiveness despite the losses incurred during the reporting period [3].

Core Insights - The company reported a significant decline in revenue and net profit for the year 2025, with total revenue of 142 million yuan, a decrease of 46.09% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 137.25 million yuan, indicating a challenging financial period [1] - Factors contributing to the decline include intensified market competition due to domestic pharmaceutical procurement policies and the introduction of similar competing products, as well as a lower incidence of flu in the domestic market during the first three quarters of 2025 [1] Financial Performance - The company's operating revenue for 2025 was 142 million yuan, down 46.09% year-on-year [1] - The net profit attributable to the parent company was a loss of 137.25 million yuan [1] - Despite the losses, the company managed to significantly reduce the loss margin compared to the previous year [1] Market Conditions - The domestic pharmaceutical industry is experiencing increased competition due to the deepening implementation of centralized procurement policies and the launch of similar competing products [1] - The lower incidence of flu in the domestic market during the first three quarters of 2025 has also negatively impacted revenue and gross margin [1] Strategic Initiatives - The company has maintained a high level of research and development investment to sustain its core competitiveness, despite the financial losses [1] - Asset impairment losses and credit impairment losses were recognized based on prudence principles in accordance with accounting standards [1]

Group 1 - Company Nanjing New Pharmaceutical reported a revenue of approximately 142 million yuan for the year 2025, representing a year-on-year decrease of 46.09% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 137 million yuan [1] - The basic earnings per share showed a loss of 0.5006 yuan [1] Group 2 - The news highlights a significant shift in AI usage, with China's AI call volume surpassing that of the United States, leading to a surge in multiple sectors in the A-share market [1] - A well-known Wall Street analyst noted that China's computing power path is overturning traditional perceptions [1]

Group 1 - The core point of the article is that Nanjing New Pharmaceutical reported a significant decline in revenue for the year 2025, with total operating income reaching 1,419.276 million yuan, a year-on-year decrease of 46.09% [2] Group 2 - The company’s performance indicates a substantial drop in revenue, which may raise concerns about its market position and operational efficiency moving forward [2] - The announcement was made on February 27, highlighting the urgency of the financial situation [2] - The reported figures suggest potential challenges in the pharmaceutical industry, particularly for companies experiencing such drastic revenue declines [2]

Financial Performance - Total revenue for 2025 was CNY 141.93 million, a decrease of 46.09% compared to the previous year[4] - Operating profit for 2025 was CNY -132.51 million, with a total profit of CNY -132.67 million[4] - Net profit attributable to shareholders was CNY -137.25 million, a significant decline from CNY -356.90 million in the previous year[4] - Basic earnings per share for 2025 was CNY -0.5006, improving from CNY -1.3007 year-on-year[4] Assets and Equity - Total assets at the end of 2025 were CNY 809.54 million, down 33.78% from the previous year[6] - Shareholders' equity attributable to the parent company decreased to CNY 783.20 million, a reduction of 16.38%[6] Return on Investment - The weighted average return on net assets improved by 16.03 percentage points to -15.84%[4] Market Conditions - The company faced intensified market competition due to domestic pharmaceutical procurement policies and the introduction of similar products[7] Research and Development - The company maintained high R&D investment to sustain core competitiveness despite the losses[7] Financial Management - The company successfully reduced interest-bearing liabilities and accounts payable, leading to a lower asset-liability ratio[9]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has announced a projected loss for the fiscal year 2025, with significant declines in both revenue and net profit compared to the previous year [1] Group 1: Financial Performance - The company expects to achieve an operating income of between 120 million to 150 million yuan for 2025, representing a decrease of 113.28 million to 143.28 million yuan, or a decline of 43.03% to 54.42% year-on-year [1] - The projected net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, equating to a year-on-year decrease in loss of 55.17% to 66.38% [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan year-on-year, reflecting a decrease in loss of 53.98% to 65.14% [1] Group 2: Historical Financial Data - From 2021 to 2024, the net profits attributable to the shareholders of the listed company were -162 million yuan, -78.83 million yuan, -10.87 million yuan, and -357 million yuan respectively [2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and a total of 35 million shares issued [2] - The total amount raised from the initial public offering was 1.223 billion yuan, with a net amount of 1.135 billion yuan, exceeding the originally planned fundraising by 466 million yuan [2] Group 3: Equity Distribution - On July 16, 2022, the company announced a rights distribution plan, increasing its total share capital from 140 million shares to 196 million shares by distributing 0.4 shares for every share held [3] - On June 7, 2023, another rights distribution was announced, increasing the total share capital from 196 million shares to 274.4 million shares, again distributing 0.4 shares for every share held [3]

Core Viewpoint - Nanjing Pharmaceutical is attempting to alleviate operational pressure by transferring part of its accounts receivable through public listing, amidst ongoing losses and challenges in transformation and internal control [1][3]. Group 1: Financial Operations - The company plans to transfer accounts receivable totaling 48.98 million yuan, with a book value of 2.99 million yuan after accounting for bad debt provisions of 45.98 million yuan [2]. - Nanjing Pharmaceutical has been in a continuous loss state since its IPO in 2020, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, and a net profit loss of 357 million yuan in 2024 [3][4]. Group 2: Product Challenges - The core product, Peramivir Sodium Injection, which accounted for 73.5% of revenue in 2020, has faced increased competition after its market protection period expired in 2018, leading to a 43.51% price reduction in 2023 [4]. - The company has not disclosed sales revenue for Peramivir since 2020, indicating a significant decline in its market position [4]. Group 3: Acquisition Attempts - Nanjing Pharmaceutical attempted to acquire assets from Future Pharmaceuticals for up to 480 million yuan to diversify its product line, but the deal was terminated due to disagreements on key terms [6][7]. Group 4: Financial and Regulatory Challenges - The company faces increasing financial pressure, with total assets of 1.034 billion yuan and liabilities of 233 million yuan, resulting in a debt ratio of 22.57% [8]. - Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for alleged violations in annual report disclosures, further complicating its financial situation [8].

Group 1 - The company held its first extraordinary general meeting of shareholders on February 11, 2026, in Guangzhou, with no resolutions being rejected [2] - The meeting was convened by the board of directors and chaired by Mr. Zhang Shixi, using a combination of on-site and online voting methods, complying with relevant laws and regulations [2][3] - The company successfully elected independent directors to the second board of directors during the meeting [4][5] Group 2 - Mr. Zhang Shixi submitted his resignation as general manager due to work adjustments, effective immediately upon delivery to the board [9] - The board appointed Mr. Chen Jianxu as the new general manager, with a term lasting until the end of the current board's term [9][12] - Mr. Chen Jianxu has a background in the pharmaceutical industry and has held various positions in reputable companies, ensuring his qualifications meet legal and regulatory requirements [13][14] Group 3 - The company plans to publicly transfer part of its accounts receivable held by a subsidiary through the Hunan United Property Exchange [15][16] - The total accounts receivable to be transferred amounts to 489.784 million yuan, with a provision for bad debts of 459.7945 million yuan, resulting in a book value of 29.9895 million yuan [17][20] - The transaction aims to optimize the company's asset structure and improve liquidity, with the final transaction price to be determined through public bidding [27][24]